Regenerative Medicine Market is projected to reach USD 40.6 billion by 2027 from USD 12.2 billion in 2022, at a CAGR of 27.2% according to a new report by MarketsandMarkets™. The major factors driving the growth of the regenerative medicine market are the availability of funding and rising investments in R&D, increasing clinical trials for stem cells and CAR-T cell therapies, and rising advancements in tissue engineered products.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579
Browse in-depth TOC on “Regenerative Medicine Market”
193 – Tables
49 – Figures
192 – Pages
Regenerative Medicine Market Scope:
|
Report Coverage |
Details |
|
Market Size |
USD 40.6 billion by 2027 |
|
Growth Rate |
27.2% of CAGR |
|
Largest Market |
North America |
|
Market Dynamics |
Drivers, Restraints, Opportunities & Challenges |
|
Forecast Period |
2022-2027 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Product, Application, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Report Highlights |
Updated financial information / product portfolio of players |
|
Key Market Opportunities |
Implementation of the 21st Century Cures Act |
|
Key Market Drivers |
Growing prevalence of chronic diseases, genetic disorders, and cancer |
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=65442579
Cell therapy segment accounted for the largest share of the regenerative medicine market
Based on the product, the regenerative medicine market is segmented into musculoskeletal disorders, oncology, dermatology & wound care, ophthalmology, cardiovascular diseases, and other applications. In 2021, the musculoskeletal disorders segment accounted for the largest share of the global regenerative medicine market. Growth in this market segment can be attributed to the rising research on musculoskeletal regeneration and prevalence of orthopedic disorders.
Musculoskeletal disorder is the largest-growing application segment of the regenerative medicine market
Based on application, the regenerative medicine market is segmented into academic & research institutes, contract research organizations (CROs), and pharmaceutical & biotechnology companies. In 2021, the academic & research institutes segment accounted for the largest share of the regenerative medicine market. Market growth can largely be attributed to the increase in research intensity in this end-user segment and the availability of sufficient grants and funds for research.
North America accounted for the largest share of the regenerative medicine market
North America held the largest share in the global market, followed by Europe. The large share of the North American regional segment can be attributed to the increase in research targeted toward developing cell-based therapies in the past decade and increasing research activities in regenerative medicine and growing awareness of personalized medicine have also resulted in the establishment of stem cell banking and tissue engineering.
Regenerative Medicine Market Dynamics:
Drivers:
- Rising prevalence of chronic diseases, genetic disorders, and cancer
- Rising investments in regenerative medicine research
- Growing pipeline of regenerative medicine products
Restraints:
- Ethical concerns related to the use of embryonic stem cells in research & development
- High cost of cell and gene therapies
Opportunities:
- Implementation of the 21st Century Cures Act
- Rising demand for organ transplantations
Key Market Players:
The regenerative medicine market is consolidated in nature with prominent players in the regenerative medicine market include Novartis AG (Switzerland), Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen, Inc. (US), Smith & Nephew plc (UK), Medipost Co., Ltd. (South Korea), JCR Pharmaceuticals Co., Ltd (Japan), Takeda Pharmaceutical Company (Japan), CORESTEM, Inc (South Korea), Vericel Corporation (US), MIMEDX (US), Organogenesis Inc. (US), Medtronic plc (US), Orthocell Ltd. (Australia), Mesoblast Ltd (Australia), BioRestorative Therapies, Inc (US), Pluri Inc. (Israel), Tegoscience (South Korea), Anterogen Co., Ltd. (South Korea), bluebird bio, Inc. (US), APAC Biotech (India), Shenzhen SiBiono Genetech Co., Ltd. (China), Aspect Biosystems (Canada), and Athersys, Inc. (US).
Recent Developments:
- In 2022, Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function.
- In 2020, AbbVie acquired Allergan to enhance its product portfolio in immunology, hematologic oncology, neuroscience, and Allergan aesthetics.
- In 2022, MiMedx announced the launch of Axiofill, an Extracellular Matrix (ECM) Particulate product derived from human placental tissue. Axiofill is a human placental-derived particulate product available for surgical recovery procedures.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=65442579
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/regenerative-medicine-market-65442579.html